What are the causes of oligomenorrhea?

Causes of Oligomenorrhea

Oligomenorrhea (menstrual cycles lasting 36-90 days) is most commonly caused by polycystic ovary syndrome (PCOS), accounting for approximately 50-70% of cases, followed by functional hypothalamic amenorrhea (FHA) in 20-35% of cases, with other endocrine disorders comprising the remainder. 1, 2, 3

Primary Causes by Frequency

Polycystic Ovary Syndrome (PCOS) - Most Common

• PCOS represents 51-70% of oligomenorrhea cases, making it the leading cause in women of reproductive age 2, 3
• Characterized by hyperandrogenemia (elevated testosterone and/or DHEA-sulfate in 41.8% of oligomenorrheic patients), polycystic ovarian morphology on ultrasound (≥20 follicles per ovary of 2-9mm), and chronic anovulation 1, 4
• Associated features include hirsutism (strong diagnostic pointer), obesity, insulin resistance, acanthosis nigricans, and elevated LH:FSH ratio 1, 3
• Higher body mass index, elevated anti-Müllerian hormone (AMH), and lower sex hormone-binding globulin (SHBG) levels are characteristic 1

Functional Hypothalamic Amenorrhea (FHA) - Second Most Common

• FHA accounts for 20-35% of secondary amenorrhea/oligomenorrhea cases and represents the second most common cause 1
• Results from reduced pulsatile GnRH secretion leading to decreased LH and FSH levels, causing anovulation 1
• Key triggers include: stress and psychological disorders, vigorous exercise (particularly ≥7 hours/week of low-intensity or ≥5 hours/week of high-intensity training), weight loss, and energy deficit 1, 5
• Characterized by low or normal BMI, signs of estrogen deficiency, negative progestin challenge test, and low energy availability 1
• Prevalence of PCOM in FHA patients is surprisingly high at 41.9-46.7%, which can create diagnostic confusion with PCOS 1

Hyperandrogenic Oligomenorrhea in Athletes - Important Subgroup

• In exercising women with oligomenorrhea, approximately 17% have concurrent hyperandrogenism rather than hypothalamic suppression 6
• This subgroup demonstrates higher BMI, body fat percentage, insulin, leptin, free androgen index (FAI 6.1 vs 1.7), and LH:FSH ratio compared to hypothalamic oligomenorrhea 6, 7
• These women show more anabolic body composition with higher bone mineral density and may have performance advantages 7

Hyperprolactinemia

• Accounts for approximately 25.9% of oligomenorrheic patients (with overlap possible with other conditions) 4
• Must be excluded through prolactin level measurement 1

Thyroid Dysfunction

• Abnormal thyroid function (TSH and/or TRH-induced TSH) found in 21.7% of oligomenorrheic patients 4
• Both hypothyroidism and hyperthyroidism can cause menstrual irregularities 1

Primary Ovarian Insufficiency

• Hypergonadotropic FSH levels found in 3.5% of oligomenorrheic patients 4
• More common in amenorrheic than oligomenorrheic patients 4

Other Endocrine Causes (Each <10%)

• Cushing's syndrome: Look for buffalo hump, moon facies, hypertension, abdominal striae, centripetal fat distribution, easy bruising, or proximal myopathies 1
• Androgen-secreting tumors: Consider when total testosterone is markedly elevated 1
• Nonclassic congenital adrenal hyperplasia: Screen with 17-hydroxyprogesterone 1
• Acromegaly and genetic defects in insulin action: Rare causes 1

Diagnostic Pitfalls and Key Differentiators

FHA-PCOM vs PCOS Phenotype D

This distinction is particularly challenging as both present with oligomenorrhea and PCOM without overt hyperandrogenism 1:

Favor FHA-PCOM when:

• Low or normal BMI with evidence of energy deficit 1
• History of excessive exercise, dietary restriction, or significant psychological stress 1
• Lower testosterone and higher SHBG levels 1
• Negative progestin challenge test 1
• Lower LH response to GnRH stimulation 1

Favor PCOS when:

• Higher BMI and body fat percentage 1
• Elevated AMH, testosterone, and lower SHBG 1
• Higher LH:FSH ratio and greater LH response to GnRH testing 1

Age and Duration Considerations

• In the first 5 years after menarche, oligomenorrhea may be physiological and accounts for approximately 10% of cases 2, 3
• Women >20 years old or >10 years post-menarche have higher frequency of PCOS and lower prevalence of hypothalamic dysfunction 2
• Oligomenorrhea persisting beyond 5 years post-menarche or appearing after normal cycles warrants full evaluation 2

Clinical Implications

Metabolic and Cardiovascular Risk

• Women with PCOS have increased risk for type 2 diabetes, dyslipidemia (elevated LDL, triglycerides, low HDL), hypertension, and cardiovascular disease 1, 2
• All women with PCOS should undergo fasting glucose followed by 2-hour glucose tolerance test with 75-gram glucose load 1
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) should be obtained in all PCOS patients 1

Fertility Considerations

• Infertility rates are significantly higher in oligomenorrheic women (17.2%) compared to those with normal cycles (9.0%) 8
• Among women not using contraception, infertility rate reaches 32.5% in the oligomenorrhea group 8
• Approximately 89% of oligomenorrheic women have anovulatory cycles 2

Long-term Consequences

• Chronic anovulation with unopposed estrogen increases endometrial cancer risk, particularly with obesity and hyperinsulinemia 1
• FHA patients risk reduced bone mineral density due to hypoestrogenism 1